Sunita D. Nasta, MD, FACP
Professor of Clinical Medicine (Hematology-Oncology)
Attending Physician, Hospital of the University of Pennsylvania
Chair, Clinical Trials Scientific Research Monitoring Committee
Chair, Hospital University of Pennsylvania Credentialing Committee
Lymphoma Section Chief, Division of Hem/Onc
Department of Medicine
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-159
3400 Civic Center Boulevard
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-159
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-3933
Fax: 215-615-5887
Fax: 215-615-5887
Education:
BS (Microbiology & Immunology)
Stanford University, Palo Alto, CA , 1991.
MD
Medical College of Virginia, Richmond, VA, 1995.
Permanent linkBS (Microbiology & Immunology)
Stanford University, Palo Alto, CA , 1991.
MD
Medical College of Virginia, Richmond, VA, 1995.
Description of Research Expertise
Clinical trials in non-Hodgkin's lymphoma, phase I, II and IIIClinical trials in Castleman Diseaes
Description of Clinical Expertise
1.Management of patients with Non-Hodgkin's lymphoma, Hodgkin's Lymphoma, multiple myeloma, acute and chronic leukemias with standard therapy as well as clinical experimental therapies using new agents.2. Bone Marrow and Stem Cell Transplantation, autologous and allogeneic.
3. Special interest in treating patients with aggressive non-Hodgkin's lymphoma, lymphoma in the elderly and lymphoma in the pregnant patient.
4. Special interest in the long-term follow-up of patients with Hodgkin's lymphoma and survivors issues.
5. Management of patients with histiocytic disorders
6. Management of patients with Castleman disease.
Selected Publications
Ward RE, Dave N, Pai EL, Colbourn R, Banihashemi A, Nasta SD, Babatunde VD.: Methotrexate-associated Peripheral Neuropathy on 18F-FDG PET/CT and MRI Masquerading as Neurolymphomatosis. Clin Nucl Med. Page: Online ahead of print. Apr 18 2025 Notes: doi: 10.1097/RLU.0000000000005899.Elghawy O, Sussman JH, Yang AG, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK.: Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome. JAMA Dermatol. Page: e250251, Apr 2 2025 Notes: doi: 10.1001/jamadermatol.2025.0251.
Potluri VS, Zhang S, Schaubel DE, Shaikhouni S, Blumberg EA, Nasta SD, Bloom RD, Cruz-Peralta M, Mehta RB, Lavu NR, Getachew B, Tandukar S, Reese PP, Puttarajappa CM. : The Association of Epstein-Barr Virus Donor and Recipient Serostatus With Outcomes After Kidney Transplantation : A Retrospective Cohort Study. Ann Intern Med. 178(2): 157-166, Feb 2025 Notes: doi: 10.7326/ANNALS-24-00165. Online ahead of print. PMID:
Canty EA, Broderick L, Flaherty D, Xavier M, Nasta SD, Dajani L, White AA.: First reported case of a spontaneous and healthy pregnancy in a woman with persistent CAR T-cells 5 years after treatment for diffuse large B-cell lymphoma. J Immunother Cancer. 13(4): e011092, Apr 1 2025 Notes: doi: 10.1136/jitc-2024-011092.
Pierson SK, Brandstadter JD, Torigian D, Bagg A, Lechowicz MJ, Alapat D MD, Casper C, Chadburn A, Chandrakasan S, Dispenzieri A, Fosså A, Hoffmann C, Ide M, Kurzrock R, Mukherjee S, Nasta SD, Navarro JT, Noy A, Oksenhendler E, Sarmiento Bustamante M, Shyamsundar S, Streetly MJ, Wong RSM, Zhang L, Lim MS, Srkalovic G, van Rhee F, Fajgenbaum DC. : Characterizing the heterogeneity of Castleman disease and oligocentric subtype: Findings from the ACCELERATE registry. Blood Adv. Feb 14 2025 Notes: bloodadvances.2024014391. doi: 10.1182/bloodadvances.2024014391. Online ahead of print.
Elghawy O, Wang J, Leung OJ, Swami N, Carvajal V, Yang G, Landsburg DJ, Svoboda J, Nasta SD, Chong EA, Schuster SJ, Thomas CJ, Carter JS, Bagg A, Barta SK. : Clinical Impact of Next-Generation Sequencing of T-Cell Lymphomas: A Single Institution Experience. Clin Lymphoma Myeloma Leuk. S2152-2650(25): 35-7, Feb 3 2025 Notes: doi: 10.1016/j.clml.2025.01.017. Online ahead of print.
Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ. : Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B Cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy. Transplant Cell Ther. S2666-6367(25), Jan 21 2025 Notes: doi: 10.1016/j.jtct.2025.01.884. Online ahead of print. PMID:
Ni V, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Morrissette JJD, Barlev A, Bagg A, Priore SF, Landsburg DJ. PMID: : Identification of a clinicopathologic prognostic index for newly diagnosed large B cell lymphoma patients treated with R-CHOP. Haematologica Nov 28 2024 Notes: doi: 10.3324/haematol.2024.286560. Online ahead of print.
Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. : Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. S0190-9622(24), Nov 16 2024 Notes: doi: 10.1016/j.jaad.2024.10.095. Online ahead of print.
Landsburg DJ, Morrissette JJD, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Barlev A, Bagg A, Priore SF. : Genomic Features of Newly Diagnosed Large B-cell Lymphoma with or without Subsequent Disease Progression. Cancer Res Commun. 4(11): 2947-2954, nov 1 2024 Notes: doi: 10.1158/2767-9764.CRC-24-0337.